Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
NCT ID: NCT04175262
Last Updated: 2023-05-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
102 participants
OBSERVATIONAL
2019-10-31
2020-03-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
NCT04076787
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
NCT01934452
Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
NCT01499121
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
NCT00694096
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
NCT02060370
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with mRCC
Patients diagnosed with metastatic RCC receiving first line (1L) combination of IOs therapies followed by Sunitinib as a second line (2L) treatment
sunitinib
Patients to receive sunitinib as second line therapy for mRCC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sunitinib
Patients to receive sunitinib as second line therapy for mRCC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received IO therapy as 1L therapy
* Received sunitinib as 2L therapy
* Age 18 years or over at the time of mRCC diagnosis
* Actively treated at an IMDC clinical center (to avoid incomplete data)
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
OTHER
Analysis Group, Inc.
INDUSTRY
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6181233
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.